Prostate Cancer Awareness Month: Financial hardship common, exercise beneficial
Click Here to Manage Email Alerts
National Prostate Cancer Awareness Month is observed every September.
An estimated 288,300 men in the United States will be diagnosed with prostate cancer this year and about 34,700 men will die of the disease, according to American Cancer Society.
National Prostate Cancer Awareness Month is intended to educate men about prostate cancer risk factors, screening and treatment options.
In conjunction with the observance, Healio presents the following updates in prostate cancer research that may be relevant to your practice.
1. More than half of men treated for metastatic prostate cancer reported experiencing some degree of financial hardship. Read more.
2. Researchers discovered a biological mechanism among men with diabetes and metastatic prostate cancer that they believe may lay the foundation for better testing and treatments for Black men with both diseases. Read more.
3. Shared decision-making could attenuate racial disparities in prostate cancer screening. Read more.
4. The combination of cabozantinib (Cabometyx, Exelixis) and atezolizumab (Tecentriq, Genentech) prolonged PFS compared with second novel hormonal therapy for men with metastatic castration-resistant prostate cancer. Read more.
5. The FDA approved niraparib and abiraterone acetate (Akeega, Janssen Biotech) with prednisone for the treatment of deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer. Read more.
6. Men with very high-risk prostate cancer treated at high-volume radiation therapy treatment facilities survived significantly longer than those treated at low-volume centers. Read more.
7. Black men with metastatic castration-sensitive prostate cancer achieved OS and PFS comparable to white men when treated in a clinical trial setting. The findings suggest equal access to health care resources can help alleviate racial disparities in survival among Black men with advanced prostate cancer. Read more.
8. Supervised resistance and aerobic exercise appeared to improve sexual function among men with prostate cancer. Read more.
9. Magnetic resonance-guided daily adaptive stereotactic body radiotherapy appeared associated with a reduction in acute toxicity compared with a more common technique for men with prostate cancer. Read more.
10. The FDA approved talazoparib (Talzenna, Pfizer) plus enzalutamide (Xtandi; Astellas, Pfizer) for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Read more.
Reference:
American Cancer Society. Key statistics for prostate cancer. Available at: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html. Accessed Sept. 2, 2023.
Collapse
Healio Coverage
Click Here to Manage Email Alerts